Disease · MONDO_0019340

scleroderma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. scleroderma. Diseases, record MONDO_0019340. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019340

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: scleroderma; Open Targets
Open Targets ID: MONDO_0019340; Open Targets
Other names: Morphea "en coup de sabre", Progressive systemic scleroderma, Pseudoscleroderma, dermatosclerosis, linear scleroderma, localized scleroderma, morphea, scleroderma (disease); Open Targets
Disease Ontology: DOID:419; Disease Ontology
NCI Thesaurus: C26746; NCI Thesaurus
Orphanet: ORPHA:801; Orphanet
Highest stage of its drugs: Phase 3, for 5 of its 25 drugs, from ClinicalTrials.gov; Open Targets

Drugs25

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SILDENAFIL	CHEMBL192	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INTERLEUKIN 6	CHEMBL2074847		Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DUPILUMAB	CHEMBL2108675	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB	CHEMBL941	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 25

See all 25 drugs

Targets36

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
TGFB1	Transforming growth factor beta-1 proprotein	2	Transforming growth factor beta-1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/7040	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/7915	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 1/2	https://conductscience.org/library/genes/1719	Drugs and targets
F2	Prothrombin	1	Thrombin inhibitor	Phase 1	https://conductscience.org/library/genes/2147	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1/2	https://conductscience.org/library/genes/2280	Drugs and targets
IFNAR1	Interferon alpha/beta receptor 1	1	Interferon-alpha/beta receptor alpha chain antagonist	Phase 1	https://conductscience.org/library/genes/3454	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 2	https://conductscience.org/library/genes/3566	Drugs and targets

1 to 10 of 36

See all 36 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00848107	Open-Label Study of Oral Treprostinil in Digital Ulcers	Phase 2	115	2014-02-07	Systemic Sclerosis	TREPROSTINIL DIOLAMINE	Its record names the disease	ClinicalTrials.gov
NCT01445821	Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Phase 3	44	2020-07-23	Scleroderma, Systemic	CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT01166139	Nilotinib in the Treatment of Systemic Sclerosis	Phase 2	10	2017-10-04	Systemic Sclerosis	NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT02503644	Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis	Phase 2	145		Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis	LANIFIBRANOR	Its record names the disease	ClinicalTrials.gov
NCT01295736	Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY	Phase 3	84		Systemic Scleroderma	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT05963048	Rituxmab Versus IL-6 in Treating ILD	Phase 2/3	60		Interstitial Lung Disease, Scleroderma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT04200755	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma	Phase 2	45		Localized Scleroderma	DUPILUMAB	Its record names the disease	ClinicalTrials.gov
NCT00930683	A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma	Phase 1	34		Scleroderma	ANIFROLUMAB	Its record names the disease	ClinicalTrials.gov
NCT04797286	Sildenafil for Early Pulmonary Vascular Disease in Scleroderma	Phase 2	30		Scleroderma, Mildly Elevated Pulmonary Pressures	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT00740285	Effectiveness and Safety of Lidocaine for Scleroderma	Phase 2/3	26		Scleroderma	LIDOCAINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cyclophosphamide rATG/HSCT vs Cyclophosphamide rATG/Fludarabine/HSCT: Survival of Treatment	22 of 22	21 of 22	44	NCT01445821	Trial comparisons
Cyclophosphamide rATG/HSCT vs Cyclophosphamide rATG/Fludarabine/HSCT: deaths from any cause	2 of 22	3 of 22	44	NCT01445821	Trial comparisons
Cyclophosphamide rATG/HSCT vs Cyclophosphamide rATG/Fludarabine/HSCT: serious adverse events	2 of 22	3 of 22	44	NCT01445821	Trial comparisons
Cyclophosphamide rATG/HSCT vs Cyclophosphamide rATG/Fludarabine/HSCT: Number of Participants With Treatment Failure	2 of 17	2 of 15	32	NCT01445821	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25995322	RESULT	1	PubMed
19950289	RESULT	1	PubMed
42957460	DERIVED	1	PubMed
40013233	DERIVED	1	PubMed
38689245	DERIVED	1	PubMed
28298564	DERIVED	1	PubMed
26283632	DERIVED	1	PubMed
26098215	DERIVED	1	PubMed
24850877	DERIVED	1	PubMed
24559157	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019340

GET https://conductscience.org/api/diseases/v1/MONDO_0019340/drugs?page=2

API reference For AI assistants